According to the Zhitong Finance App, Youzhiyou Bio-B (02496.HK) announced that the company has completed the first patient administration in a phase I clinical study of the Aimesajudan biosimilar drug Y225 in China. This phase I clinical trial is a randomized, double-blind, single-dose, parallel comparison study. The aim is to evaluate the bioequivalence between Y225 and the reference drug Shuyoulilac® (emicerizumab injection) in healthy male subjects, and to provide a basis for subsequent clinical development of Y225. This marks the entry of the project into clinical research in humans.

According to the Zhitong Finance App, Youzhiyou Bio-B (02496.HK) announced that the company has completed the first patient administration in a phase I clinical study of the Aimesajudan biosimilar drug Y225 in China. This phase I clinical trial is a randomized, double-blind, single-dose, parallel comparison study. The aim is to evaluate the bioequivalence between Y225 and the reference drug Shuyoulilac® (emicerizumab injection) in healthy male subjects and provide a basis for subsequent clinical development of Y225. This marks the entry of the project into clinical research in humans.